Home Protein Tyrosine Kinase Insulin Receptor

Insulin Receptor

Protein Tyrosine Kinase

VEGFR EGFR IGF-1R c-Met c-Kit ALK Tie-2 HER2 PDGFR c-RET Trk receptor TAM receptors (Tyro-3,Axl,and Mertk) CSF-1R Ephrin receptor ACK DDR ROS1 Pyk2 Tyro3 Axl Mertk Fer kinase RON
  • All (2)
  • Insulin Receptor Inhibitor (1)
  • Insulin Receptor Antagonist (1)
  • New Insulin Receptor Products
Cat.No. Product Name Information Product Use Citations Product Validations
S1091 Linsitinib (OSI-906) Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays. It is modestly potent to InsR with IC50 of 75 nM, and shows no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Nat Commun, 2025, 16(1):2493
Cell Rep Med, 2025, 6(8):102297
Cell Rep Med, 2025, 6(8):102254
Verified customer review of Linsitinib (OSI-906)
S6922 S961 S961 is a biosynthetic insulin receptor antagonist that inhibits cellular proliferation and colony formation in breast tumour cells.
Front Immunol, 2025, 16:1620571
Hepatol Commun, 2025, 9(9)e0793
J Neuroendocrinol, 2024, e13446.
S1091 Linsitinib (OSI-906) Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays. It is modestly potent to InsR with IC50 of 75 nM, and shows no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Nat Commun, 2025, 16(1):2493
Cell Rep Med, 2025, 6(8):102297
Cell Rep Med, 2025, 6(8):102254
 Verified customer review of Linsitinib (OSI-906)
S6922 S961 S961 is a biosynthetic insulin receptor antagonist that inhibits cellular proliferation and colony formation in breast tumour cells.
Front Immunol, 2025, 16:1620571
Hepatol Commun, 2025, 9(9)e0793
J Neuroendocrinol, 2024, e13446.